Back to Search
Start Over
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
- Source :
-
The Journal of urology [J Urol] 2020 Apr; Vol. 203 (4), pp. 684-689. Date of Electronic Publication: 2019 Oct 09. - Publication Year :
- 2020
-
Abstract
- Purpose: We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic implications using prospective, randomized controlled data.<br />Materials and Methods: We queried the ASSURE (Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery) (ECOG-ACRIN [Eastern Cooperative Oncology Group-American College of Radiology Imaging Network] E2805) trial data for patients with fully resected, intermediate-high risk, nonmetastatic renal cell carcinoma with local recurrence. We used certain definitions, including type I-single recurrence in a remnant kidney or ipsilateral renal fossa, type II-single recurrence in the ipsilateral vasculature, the ipsilateral adrenal gland or a lymph node, type III-single recurrence in other intra-abdominal soft tissues or organs and type IV-any combination of types I-III or multiple recurrences of a single type. Multivariable logistic regression and the log rank test were performed to identify clinicopathological predictors and compare survival, respectively.<br />Results: Of the 1,943 patients 300 (15.4%) had local recurrence, which was type I, II, III and IV in 66 (22.0%), 97 (32.3%), 87 (29.0%) and 50 (16.7%), respectively. Surgical modality (minimally invasive vs open) and type of surgery (partial vs radical) did not predict any local recurrence. Five-year cancer specific survival and overall survival were worse in patients with type IV recurrence (each p <0.001). There was no difference in survival among patients with types I to III recurrence.<br />Conclusions: In patients with intermediate-high risk nonmetastatic renal cell carcinoma local recurrence appears to be a function of biology more than of surgical modality or surgery type. The prognosis for solitary intra-abdominal local recurrences appear similar regardless of location (types I-III). Local recurrences involving multiple sites and/or subdivisions are associated with worse survival (type IV).
- Subjects :
- Adult
Aged
Antineoplastic Agents therapeutic use
Carcinoma, Renal Cell diagnostic imaging
Carcinoma, Renal Cell mortality
Carcinoma, Renal Cell pathology
Chemotherapy, Adjuvant methods
Clinical Trials, Phase III as Topic
Disease-Free Survival
Female
Follow-Up Studies
Humans
Kidney diagnostic imaging
Kidney surgery
Kidney Neoplasms diagnostic imaging
Kidney Neoplasms pathology
Male
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence, Local diagnostic imaging
Neoplasm Recurrence, Local pathology
Neoplasm Staging
Prognosis
Prospective Studies
Randomized Controlled Trials as Topic
Risk Assessment
Sorafenib therapeutic use
Sunitinib therapeutic use
Carcinoma, Renal Cell therapy
Kidney pathology
Kidney Neoplasms mortality
Kidney Neoplasms therapy
Neoplasm Recurrence, Local epidemiology
Nephrectomy
Subjects
Details
- Language :
- English
- ISSN :
- 1527-3792
- Volume :
- 203
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The Journal of urology
- Publication Type :
- Academic Journal
- Accession number :
- 31596672
- Full Text :
- https://doi.org/10.1097/JU.0000000000000588